Edgewise Therapeutics, Inc. 8K

Edgewise Therapeutics sold its sevasemten muscular dystrophy program to Servier for $1.55 billion upfront plus up to $1.1 billion in milestones, recognized a substantial gain and related tax liability, and issued pro forma financials reflecting the significant disposition and refocus on cardiovascular assets.

On May 31, 2026, Edgewise Therapeutics, Inc. entered into a definitive Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier under which Servier acquired Edgewise’s sevasemten muscular dystrophy program, including associated intellectual property, know‑how, selected employees, contracts, regulatory filings, and clinical data, and the transaction closed on July 10, 2026. Edgewise received $1.55 billion in upfront cash and may earn up to an additional $1.1 billion in regulatory and commercial milestone payments, for total potential consideration of $2.65 billion; the disposed assets are treated as nonfinancial assets rather than a business under U.S. GAAP, and the company recorded a large nonrecurring gain on sale, associated tax liabilities, and a transition services obligation reflecting below‑market support services to be provided to Servier. The company’s pro forma financials show a substantial increase in cash, elimination of sevasemten‑related operating expenses, recognition of income tax expense related to the gain, and presentation of a Transition Services Agreement under which Edgewise will perform certain services and be partially reimbursed, while Edgewise refocuses its pipeline as a cardiovascular‑focused company centered on EDG‑7500, EDG‑15400, and EDG‑003.

Filing Facts

CIK

1710072

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-084088

Alert Tier

8